/ EN
HOME > NEWS&EVENTS

Press Releases

JHL BIOTECH STRENGTHENS CHINA MANAGEMENT TEAM

01 Nov 2016

JHL BIOTECH STRENGTHENS CHINA MANAGEMENT TEAM

 

Hsinchu, Taiwan and Wuhan, China, November 1st, 2016 – JHL Biotech (“JHL”, Stock Code: 6540.TWO) has announced that WeiDong Cui, Ph.D. has joined JHL Biotech as Corporate VP of Manufacturing and Technology, effective today. With the addition of WeiDong, JHL has fortified a strong leadership team. Recent JHL hires include Zack Zheng, Ph.D. as VP of Wuhan Process Development; Jason Lin as Director of Procurement; James Chang as Senior Director of Wuhan QA and Validation; and Henry Wu as Director of Corporate Projects and Wuhan Engineering.

 

Dr. Cui has over 20 years' experience in biopharmaceutical manufacturing and comes to JHL from Chempartner, where he was VP of Biologics CMC. Zack Zheng, Ph.D. joined JHL after serving as a VP at Jecho BioPharm, and he brings 16 years of experience at companies including Pfizer, Wyeth, and MedImmune. Jason Lin joined JHL after 14 years at Genentech, where he assumed procurement roles in both the United States and in China. James Chang came to JHL after 20 years in quality and management related roles at Novartis, Schering-Plough, Pfizer, and MSD. Henry Wu joined JHL after an engineering career spent at Bayer and Genentech in the San Francisco Bay Area. Zack, Jason, James, and Henry all spend a significant amount of time at JHL’s new Wuhan facility and have been instrumental in start-up of JHL’s 4x2,000L KUBio API plant, which just successfully produced a 2,000L batch of cGMP material on behalf of a client.

 

“We are excited to have WeiDong join JHL Biotech as Corporate VP of Manufacturing and Technology. In his new role, Dr. Cui will be responsible for overseeing the tox, clinical, and commercial manufacture of JHL’s portfolio and contract products. JHL’s most important asset is its people. In this year alone, we have grown our Wuhan operations threefold, and with the team we have in place, I have no doubt that JHL will realize the ambitious goals we have set for ourselves,” said Racho Jordanov, CEO of JHL Biotech.

 

About JHL Biotech

JHL Biotech, Inc. (Stock Code: 6540.TWO) is a biopharmaceutical company founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan does biosimilar pre-clinical and early-clinical phase development. JHL’s facility in Wuhan, China executes commercial-scale manufacturing of biologic therapies and recently won the BioProcess International Facility of the Year Award for Excellence in Facility Design. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract work on behalf of select clients. For more information, please visit www.jhlbiotech.com.

Media Contact

Max Chan, Chief Financial Officer

Phone: +886-(0)3-658-3899 ext.700

 

Email: mchan@jhlbiotech.com